Oral Antifungal Drug Linked to Higher Rates of Miscarriage

Article

A commonly used medication, fluconazole, used to treat vaginal yeast infections, is linked to higher rates of miscarriage if used during pregnancy, found new research published in CMAJ (Canadian Medical Association Journal).

While topical treatments are first line for pregnant women with fungal infections, oral fluconazole is often used during pregnancy.

Researchers looked at data on 441,949 pregnancies from the Quebec Pregnancy Cohort between 1998 and 2015, linking to filled prescriptions listed in the Quebec Prescription Drug Insurance database. They found that taking oral fluconazole was linked to adverse outcomes.

"Our study shows that taking any dose of oral fluconazole while pregnant may be associated with a higher chance of miscarriage," says Dr. Anick Bérard of Université de Montréal. "Taking higher doses of fluconazole over 150 mg in early pregnancy may be linked to a higher chance of a newborn with a heart defect."

The study is consistent with other studies, although more research is needed as the study sizes are still small.

In a related commentary, Drs. Vanessa Paquette and Chelsea Elwood, of British Columbia Women's Hospital and Health Centre in Vancouver, BC, write, "The study re-emphasizes safe prescribing practices in pregnancy, which include confirming the correct diagnosis and then choosing the safest medication with the largest body of data in pregnancy at the lowest appropriate doses."

The paper, "Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies," was published Feb. 19, 2019.

Source: Canadian Medical Association Journal
 

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
Bug of the Month
David J. Weber, MD, MPH, president of the Society for Healthcare Epidemiology of America
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
© 2025 MJH Life Sciences

All rights reserved.